Trial Profile
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2019
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Vorinostat (Primary) ; Cytarabine; Filgrastim; Fludarabine; Sorafenib
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 22 Jan 2019 Status changed from active, no longer recruiting to discontinued.
- 15 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2015 New trial record